Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL

Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL

Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominant neurodegenerative disease caused by polyglutamine-expanded ataxin-3. In the present study, we expressed disease-causing mutant ataxin-3-Q79 in neuronal cultures of cerebellum, striatum and substantia nigra by using recombinant adenoviruse...

Full description

Bibliographic Details
Main Authors:	An-Hsun Chou, Tu-Hsueh Yeh, Yu-Li Kuo, Yu-Cheng Kao, Mei-Jie Jou, Chia-Yu Hsu, Shu-Ru Tsai, Akira Kakizuka, Hung-Li Wang
Format:	Article
Language:	English
Published:	Elsevier 2006-02-01
Series:	Neurobiology of Disease
Subjects:	Spinocerebellar ataxia type 3 Ataxin-3 Polyglutamine-expanded ataxin-3 Apoptosis Polyglutamine neurodegenerative disorders Bax
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996105002123

Similar Items

Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation
by: An-Hsun Chou, et al.
Published: (2008-07-01)

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
by: Melvin M. Evers, et al.
Published: (2013-10-01)

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3
by: An-Hsun Chou, et al.
Published: (2011-02-01)

Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
by: Jeannette Hübener, et al.
Published: (2010-04-01)

Implications of specific lysine residues within ataxin-3 for the molecular pathogenesis of Machado-Joseph disease
by: Priscila Pereira Sena, et al.
Published: (2023-05-01)

Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease
by: Ana F. Ferreira, et al.
Published: (2023-05-01)

The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster
by: Wei-Ling Tsou, et al.
Published: (2015-10-01)

Ectoine alters subcellular localization of inclusions and reduces apoptotic cell death induced by the truncated Machado–Joseph disease gene product with an expanded polyglutamine stretch
by: Kentaro Furusho, et al.
Published: (2005-10-01)

Sleep Alterations in a Mouse Model of Spinocerebellar Ataxia Type 3
by: Maria-Efstratia Tsimpanouli, et al.
Published: (2022-10-01)

Identification of the ataxin-1 interaction network and its impact on spinocerebellar ataxia type 1
by: Jiu-Ming Chen, et al.
Published: (2022-07-01)

Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein
by: Lianwu Fu, et al.
Published: (2005-12-01)

Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches
by: Luis C. Velázquez-Pérez, et al.
Published: (2017-09-01)

Ataxin-3 and its E3 partners: Implications for Machado-Joseph disease
by: Thomas M Durcan, et al.
Published: (2013-05-01)

Rescue of ATXN3 neuronal toxicity in Caenorhabditis elegans by chemical modification of endoplasmic reticulum stress
by: Yasmin Fardghassemi, et al.
Published: (2017-12-01)

Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and Ataxia
by: Cristy Tower, et al.
Published: (2011-01-01)

Allosteric regulation of deubiquitylase activity through ubiquitination
by: Serena eFaggiano, et al.
Published: (2015-02-01)

Machado-Joseph Disease: from first descriptions to new perspectives
by: Bettencourt Conceição, et al.
Published: (2011-06-01)

Twenty-five years since the identification of the first SCA gene: history, clinical features and perspectives for SCA1
by: Carlos Roberto Martins Junior, et al.

Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model
by: Ajayi Abiodun, et al.
Published: (2012-07-01)

Dataset on the effect of Rubicon overexpression on polyglutamine-induced locomotor dysfunction in Drosophila
by: Masaki Oba, et al.
Published: (2021-08-01)

Population genetics of spinoсerebellar ataxias caused by polyglutamine expansions
by: A. N. Shuvaev, et al.
Published: (2019-07-01)

Altered retinal structure and function in Spinocerebellar ataxia type 3
by: Vasileios Toulis, et al.
Published: (2022-08-01)

Cognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature
by: Evelyn Lindsay, et al.
Published: (2017-07-01)

Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review
by: Jun Young Park, et al.
Published: (2020-08-01)

Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila
by: Qian Zhang, et al.
Published: (2016-03-01)

Polyglutamine toxicity induces rod photoreceptor division, morphological transformation or death in Spinocerebellar ataxia 7 mouse retina
by: Marina G. Yefimova, et al.
Published: (2010-10-01)

Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model
by: Kalina Wiatr, et al.
Published: (2021-06-01)

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics
by: Rodrigo Paulino, et al.
Published: (2023-04-01)

Motor uncoordination and neuropathology in a transgenic mouse model of Machado–Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products
by: Anabela Silva-Fernandes, et al.
Published: (2010-10-01)

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion
by: Anna Niewiadomska-Cimicka, et al.
Published: (2020-06-01)

Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice
by: Ellie M. Carrell, et al.
Published: (2022-06-01)

Mutant Ataxin-2 Expression in Aged Animals Aggravates Neuropathological Features Associated with Spinocerebellar Ataxia Type 2
by: Inês T. Afonso, et al.
Published: (2022-10-01)

Mitochondrial Morphology, Function and Homeostasis Are Impaired by Expression of an N-terminal Calpain Cleavage Fragment of Ataxin-3
by: Tina Harmuth, et al.
Published: (2018-10-01)

A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3
by: Katherine J. Robinson, et al.
Published: (2021-09-01)

Proteasome degrades soluble expanded polyglutamine completely and efficiently
by: Andrej Michalik, et al.
Published: (2004-06-01)

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors
by: Fabiola V. Borbolla-Jiménez, et al.
Published: (2021-07-01)

A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities
by: Shaohong Isaac Peng, et al.
Published: (2022-09-01)

Pathogenetic Mechanisms Underlying Spinocerebellar Ataxia Type 3 Are Altered in Primary Oligodendrocyte Culture
by: Kristen H. Schuster, et al.
Published: (2022-08-01)

Clinical and genetic profile in index patients with spinocerebellar ataxia type 3 in Indonesia: case report
by: Siti Aminah, et al.
Published: (2021-07-01)

Spinocerebellar ataxia type 40: A case report and literature review
by: Han Fengyue, et al.
Published: (2021-10-01)